[Effects of combination therapy with hyperthermia and immuno-targeting chemotherapy using anti-AFP antigen on hepatocellular carcinoma].
Combination therapy with hyperthermia and immuno-targeting chemotherapy was studied using conjugate of anti-AFP-antibody and adriamycin on AFP producing hepatocellular carcinoma (HC-4) in nude mice. Experimental groups were designed as follows; A. Control B. Adriamycin alone C. Conjugate alone D. Hyperthermia alone E. Adriamycin and hyperthermia F. Conjugate and hyperthermia. Hyperthermia was performed immediately after administration of ADM-conjugate (8.0 mg/kg as ADM) or ADM alone (8.0 mg/kg). Heating in the water bath was continued for 30 minutes at 42 degrees C or 40 degrees C and drug was injected intraperitoneally. Hyperthermic therapy at 42 degrees C along with ADM-conjugate completely inhibited the tumor growth compared with others. The serum AFP was undetectable level. The effectiveness of this treatment was also histologically confirmed. Tumor concentration of ADM remained at a significantly higher level for a prolonged period comparing other groups. Growth of HC-4 was completely suppressed by the combination therapy of hyperthermia and immuno-targeting chemotherapy. One of the probable causes of this antitumor effect may be due to prolonged and high level of ADM concentration in the tumor.
First Department of Surgery, School of Medicine, Hokkaido University.
N
N
Takada
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D005260:Female; D005334:Fever; D000922:Immunotoxins / Q000627:therapeutic use*; D008114:Liver Neoplasms, Experimental / Q000473:pathology / Q000628:therapy*; D051379:Mice; D000509:alpha-Fetoproteins / Q000276:immunology*
D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D000509:alpha-Fetoproteins; D004317:Doxorubicin